Hypertension is a significant issue in Japan, impacting an estimated 43 million adults. Medtronic's Symplicity Spyral RDN system is now approved for the treatment of those patients.
GLP-1 drugs have been taking the United States by storm in recent years. According to a new study of more than 90,000 patients, some of these medications can also make a big impact on reducing adverse heart failure outcomes.
New data out of ESC Congress 2025 suggest care teams can take a more minimalist approach during a majority of TAVR cases and only treat patients with local anesthesia. In some cases, however, sedation will still be necessary.
Abbott's TAVR valve now has CE mark approval for treating low-, intermediate- and high-risk patients who present with symptomatic severe aortic stenosis. The news comes as new data on the valve's safety and effectiveness were just published in JACC: Cardiovascular Interventions.
Recor Medical's Paradise Ultrasound Renal Denervation System is the first medical device approved for the treatment of hypertension in Japan. It first gained FDA approval back in 2023.
In-hospital mortality and other key outcomes have improved in recent years, but treating these older patients is still associated with certain challenges.
Researchers used multiple AI models to evaluate EHR data from more than 322,000 heart failure patients. By identifying these subtypes, the group thinks clinicians could perform better risk assessments and make more informed treatment decisions.
Anders Gilberg, senior vice president of government affairs at the Medical Group Management Association, explains why Congress needs to renew the Medicare geographic pay adjustments in rural areas—to make payments competitive with urban areas and help retain physicians in those communities.
Hospitals are awarded Honor Roll points if they rank in one or more of the 15 specialties that U.S. News evaluates, and in one or more of the 22 procedures or conditions for patient outcomes.
